Downstream of insulin signaling are links to amyloid β (Aβ), the principle peptide that forms the plaques in brains of patients with Alzheimer's disease. It begins with insulin receptor activation turning on the phosphoinositide kinase, PI3K, which generates the lipid messenger, PIP3. PIP3 activates the signaling protein AKT (serine/threonine kinase).

AKT can affect Aβ in two ways. One is that AKT mediates the upregulation of insulin degrading enzyme, IDE, which not only breaks down insulin, but is also thought to degrade Aβ. Conversely, AKT restricts GSK3β, a kinase thought to be involved in stimulating Aβ production. The activation of either pathway can therefore reduce Aβ levels, either by degrading the...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?